Kymera Therapeutics is a technology company.
Kymera Therapeutics has raised $195.0M across 3 funding rounds.
Key people at Kymera Therapeutics.
Kymera Therapeutics has raised $195.0M in total across 3 funding rounds.
Kymera Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation (TPD) to develop oral small molecule degraders that eliminate disease-causing proteins previously considered undruggable.[1][2][5] It targets serious diseases like immunological conditions, advancing a pipeline including KT-333 (a STAT3 degrader) and others, serving patients with high unmet needs by harnessing the body's natural protein disposal system via heterobifunctional molecules.[1][2] The company's mission is to discover, develop, and commercialize transformative therapies for intractable diseases, with a vision to lead in TPD and reinvent human disease treatment through innovation and patient-centric approaches.[1][3][5]
With around 220 employees in Watertown, MA, Kymera demonstrates strong growth momentum, having advanced the first degrader into clinical trials for immunology and building an industry-leading pipeline while fostering a culture of courage, resilience, and rigor.[2][5][7]
Founded in 2016 in partnership with Atlas Venture, Kymera emerged from the recognition of a unique opportunity to pioneer TPD as a novel drug class, rethinking traditional drug discovery to address untreatable targets.[3][5] Key founders and leaders, including those reflecting on its 5-year anniversary in 2021, emphasized a long-term vision with near-term urgency, starting with targets that progressed to clinical stages, validating their early approach.[3] The idea stemmed from advancing TPD to open new therapeutic landscapes, prioritizing investments in chemistry, biology, and operations to deliver life-saving medicines.[3]
Early traction included incubating programs that reached clinical cusps, building a team of bold thinkers challenging scientific status quo, and engaging patient organizations like the National Eczema Association to inform research.[3][4] By 2024, pipeline advancements like KT-333 underscored pivotal execution.[1]
Kymera rides the TPD revolution, a transformative modality expanding druggable targets beyond traditional inhibition, addressing ~80% of the proteome previously untreatable and riding trends in precision medicine and novel biologics.[1][2][3] Timing is ideal amid biotech's shift to degraders, with market forces like rising unmet needs in immunology, oncology, and rare diseases favoring oral, convenient therapies over injectables.[2][5] Kymera influences the ecosystem by leading TPD adoption—first to clinic in immunology—setting standards for degrader design, partnering (e.g., Atlas), and mapping tools like E3 ligases, inspiring competitors and broadening therapeutic possibilities.[3][7]
Kymera is positioned to become a fully integrated degrader powerhouse, with next steps including pipeline expansions (e.g., KT-333 advancements), potential commercializations, and platform scaling beyond TPD into new modalities.[1][3] Trends like AI-driven drug discovery, proteomics integration, and immuno-oncology demand will shape its path, amplifying influence as TPD matures into mainstream biotech. As a 2016 pioneer evolving toward global leadership, Kymera's urgency in tackling undruggable targets promises to redefine treatments, delivering on its mission to transform intractable diseases.[1][3][5]
Key people at Kymera Therapeutics.
Kymera Therapeutics has raised $195.0M in total across 3 funding rounds.
Kymera Therapeutics's investors include Bessemer Venture Partners, Creacion Ventures, MPM Capital, Red Tree Venture Capital, Atlas Venture, Novartis Venture Fund, SR One, Wellington Partners.
Kymera Therapeutics has raised $195.0M across 3 funding rounds. Most recently, it raised $100.0M Series C in March 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2020 | $100.0M Series C | Bessemer Venture Partners | |
| Nov 1, 2018 | $65.0M Series B | Bessemer Venture Partners, Creacion Ventures, MPM Capital, Red Tree Venture Capital | |
| Oct 1, 2017 | $30.0M Series A | Atlas Venture, Novartis Venture Fund, SR One, Wellington Partners |
